Advertisement

Index by author

August 01, 1996; Volume 278,Issue 2

A

  1. Abe, M

    1. Novel benzodioxan derivative, 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl) amino]propoxy]-1,3-benzodioxole HCl (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models.
      M Abe, R Tabata, K Saito, T Matsuda, A Baba and M Egawa
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 898-905;

  2. Adam, A

    1. Chloramphenicol and the inflammatory response in the rat. Upregulation of the gene for T2-kininogen in liver.
      P Raymond, H Wang, C Blais, A Décarie, A Adam and R Morais
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 934-940;

  3. Agrawal, S

    1. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration.
      R Zhang, R P Iyer, D Yu, W Tan, X Zhang, Z Lu, H Zhao and S Agrawal
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 971-979;

  4. Aigner, T G

    1. D-cycloserine, a partial agonist at the glycine site coupled to N-methyl-D-aspartate receptors, improves visual recognition memory in rhesus monkeys.
      N Matsuoka and T G Aigner
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 891-897;

  5. Ali, S

    1. Simultaneous measurement of cyclopentyladenosine-induced contraction and intracellular calcium in bronchial rings from allergic rabbits and it's antagonism.
      S Ali, W J Metzger and S J Mustafa
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 639-644;

  6. Almström, S

    1. A comparison of the effects of glial cell line-derived neurotrophic factor on spinal cord and cortex cerebri grafts.
      K Trok, S Almström and L Olson
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 941-949;

  7. Anyukhovsky, E P

    1. Chronic in vivo and in vitro effects of amiodarone on guinea pig hearts.
      E A Sosunov, E P Anyukhovsky and M R Rosen
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 906-912;

  8. Apparsundaram, S

    1. Prejunctional alpha adrenoceptor desensitization in rat heart after chronic epinephrine treatment.
      S Apparsundaram and D C Eikenburg
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 862-870;

  9. Aquino, R

    1. Differential effects of muscarinic receptor agonists and phorbol ester on muscarinic and D2-dopamine release-modulatory receptors.
      I S Hoffmann, R K Talmaciu, R Aquino and L X Cubeddu
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 662-668;

  10. Arai, A

    1. Effects of a memory-enhancing drug on DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus.
      A Arai, M Kessler, G Rogers and G Lynch
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 627-638;

  11. Arnar, D O

    1. Mechanism of alpha-2 adrenergic modulation of canine cardiac Purkinje action potential.
      H C Lee, J J Cai, D O Arnar, E F Shibata and J B Martins
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 597-606;

  12. Arnold, L W

    1. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats.
      J L Valentine, M Mayersohn, W D Wessinger, L W Arnold and S M Owens
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 709-716;

  13. Atsuki, K

    1. Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle.
      K Muraki, H Nakagawa, N Nagano, S Henmi, H Kawasumi, T Nakanishi, K Imaizumi, T Tokuno, K Atsuki, Y Imaizumi and M Watanabe
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 555-563;

B

  1. Baba, A

    1. Novel benzodioxan derivative, 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl) amino]propoxy]-1,3-benzodioxole HCl (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models.
      M Abe, R Tabata, K Saito, T Matsuda, A Baba and M Egawa
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 898-905;

  2. Barth, F

    1. Characterization of two cloned human CB1 cannabinoid receptor isoforms.
      M Rinaldi-Carmona, B Calandra, D Shire, M Bouaboula, D Oustric, F Barth, P Casellas, P Ferrara and G Le Fur
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 871-878;

  3. Bauer, J

    1. Immunomodulator OM 163-induced reversal of tumor-mediated immunosuppression and downregulation of TGF-beta 1 in vivo.
      P Lagadec, S Reveneau, P Lejeune, D Pinard, T Borman, J Bauer and J F Jeannin
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 926-933;

  4. Behan, D P

    1. Regulation of corticotropin-releasing factor-binding protein expression in cultured rat astrocytes.
      D Maciejewski, P D Crowe, E B De Souza and D P Behan
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 455-461;

  5. Bellin, S

    1. Mechanisms of plumbagin action on guinea pig isolated atria.
      M Floreani, A Forlin, L Pandolfo, M Petrone and S Bellin
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 763-770;

  6. Berger, M E

    1. Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation.
      M D Nyby, M Sasaki, Y Ideguchi, H E Wynne, M T Hori, M E Berger, M S Golub, A S Brickman and M L Tuck
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 503-509;

  7. Beslot, F

    1. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
      W Gonzalez, F Beslot, I Laboulandine, M C Fournié-Zaluski, B P Roques and J B Michel
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 573-581;

  8. Bigelow, G E

    1. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans.
      K J Schuh, S L Walsh, G E Bigelow, K L Preston and M L Stitzer
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 836-846;

  9. Blais, C

    1. Chloramphenicol and the inflammatory response in the rat. Upregulation of the gene for T2-kininogen in liver.
      P Raymond, H Wang, C Blais, A Décarie, A Adam and R Morais
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 934-940;

  10. Bonanno, G

    1. Human brain cholecystokinin: release of cholecystokinin-like immunoreactivity (CCK-LI) from isolated cortical nerve endings and its modulation through GABA(B) receptors.
      M Raiteri, G Bonanno, P Paudice, P Cavazzani and G Schmid
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 747-751;

  11. Borman, T

    1. Immunomodulator OM 163-induced reversal of tumor-mediated immunosuppression and downregulation of TGF-beta 1 in vivo.
      P Lagadec, S Reveneau, P Lejeune, D Pinard, T Borman, J Bauer and J F Jeannin
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 926-933;

  12. Born, S L

    1. Escherichia coli expression and substrate specificities of canine cytochrome P450 3A12 and rabbit cytochrome P450 3A6.
      S L Born, D J Fraser, G R Harlow and J R Halpert
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 957-963;

  13. Bouaboula, M

    1. Characterization of two cloned human CB1 cannabinoid receptor isoforms.
      M Rinaldi-Carmona, B Calandra, D Shire, M Bouaboula, D Oustric, F Barth, P Casellas, P Ferrara and G Le Fur
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 871-878;

  14. Brickman, A S

    1. Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation.
      M D Nyby, M Sasaki, Y Ideguchi, H E Wynne, M T Hori, M E Berger, M S Golub, A S Brickman and M L Tuck
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 503-509;

  15. Brougham, L R

    1. Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity.
      A M Szczepanik, L R Brougham, J E Roehr, P G Conway, D B Ellis and C A Wilmot
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 913-920;

C

  1. Cai, J J

    1. Mechanism of alpha-2 adrenergic modulation of canine cardiac Purkinje action potential.
      H C Lee, J J Cai, D O Arnar, E F Shibata and J B Martins
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 597-606;

  2. Calandra, B

    1. Characterization of two cloned human CB1 cannabinoid receptor isoforms.
      M Rinaldi-Carmona, B Calandra, D Shire, M Bouaboula, D Oustric, F Barth, P Casellas, P Ferrara and G Le Fur
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 871-878;

  3. Canning, B J

    1. Inhibition by zinc protoporphyrin-IX of vasoactive intestinal peptide-induced relaxations of guinea pig isolated trachea.
      B J Undem, J L Ellis, S Meeker, A Fischer and B J Canning
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 964-970;

  4. Carr, D J

    1. Morphine suppresses the alloantigen-driven CTL response in a dose-dependent and naltrexone reversible manner.
      M Scott and D J Carr
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 980-988;

  5. Casellas, P

    1. Characterization of two cloned human CB1 cannabinoid receptor isoforms.
      M Rinaldi-Carmona, B Calandra, D Shire, M Bouaboula, D Oustric, F Barth, P Casellas, P Ferrara and G Le Fur
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 871-878;

  6. Catania, V A

    1. Ovine prolactin increases hepatic UDP-glucuronosyltransferase activity in ovariectomized rats.
      M G Luquita, V A Catania, E J Sánchez-Pozzi and A D Mottino
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 921-925;

  7. Cavazzani, P

    1. Human brain cholecystokinin: release of cholecystokinin-like immunoreactivity (CCK-LI) from isolated cortical nerve endings and its modulation through GABA(B) receptors.
      M Raiteri, G Bonanno, P Paudice, P Cavazzani and G Schmid
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 747-751;

  8. Chang, S P

    1. Vascular hyporesponsiveness in aorta from portal hypertensive rats: possible sites of involvement.
      Y T Huang, G F Wang, M C Yang, S P Chang, H C Lin and C Y Hong
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 535-541;

  9. Chavez-Noriega, L

    1. Cloning and functional characterization of human heteromeric N-methyl-D-aspartate receptors.
      S D Hess, L P Daggett, J Crona, C Deal, C C Lu, A Urrutia, L Chavez-Noriega, S B Ellis, E C Johnson and G Veliçelebi
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 808-816;

  10. Chiu, T

    1. Role of cyclic GMP-inhibitable phosphodiesterase and nitric oxide in the beta adrenoceptor control of renin secretion.
      T Chiu and I A Reid
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 793-799;

  11. Conway, P G

    1. Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity.
      A M Szczepanik, L R Brougham, J E Roehr, P G Conway, D B Ellis and C A Wilmot
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 913-920;

  12. Corradetti, R

    1. Electrophysiological effects of N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl) cyclohexane carboxamide (WAY 100635) on dorsal raphe serotonergic neurons and CA1 hippocampal pyramidal cells in vitro.
      R Corradetti, E Le Poul, N Laaris, M Hamon and L Lanfumey
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 679-688;

  13. Crona, J

    1. Cloning and functional characterization of human heteromeric N-methyl-D-aspartate receptors.
      S D Hess, L P Daggett, J Crona, C Deal, C C Lu, A Urrutia, L Chavez-Noriega, S B Ellis, E C Johnson and G Veliçelebi
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 808-816;

  14. Crowe, P D

    1. Regulation of corticotropin-releasing factor-binding protein expression in cultured rat astrocytes.
      D Maciejewski, P D Crowe, E B De Souza and D P Behan
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 455-461;

  15. Cubeddu, L X

    1. Differential effects of muscarinic receptor agonists and phorbol ester on muscarinic and D2-dopamine release-modulatory receptors.
      I S Hoffmann, R K Talmaciu, R Aquino and L X Cubeddu
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 662-668;

D

  1. Daggett, L P

    1. Cloning and functional characterization of human heteromeric N-methyl-D-aspartate receptors.
      S D Hess, L P Daggett, J Crona, C Deal, C C Lu, A Urrutia, L Chavez-Noriega, S B Ellis, E C Johnson and G Veliçelebi
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 808-816;

  2. Deal, C

    1. Cloning and functional characterization of human heteromeric N-methyl-D-aspartate receptors.
      S D Hess, L P Daggett, J Crona, C Deal, C C Lu, A Urrutia, L Chavez-Noriega, S B Ellis, E C Johnson and G Veliçelebi
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 808-816;

  3. Décarie, A

    1. Chloramphenicol and the inflammatory response in the rat. Upregulation of the gene for T2-kininogen in liver.
      P Raymond, H Wang, C Blais, A Décarie, A Adam and R Morais
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 934-940;

  4. Deplanne, V

    1. Functional characterization of alpha-1-adrenoceptor subtypes in the prostatic urethra and trigone of male rabbit.
      V Deplanne and A M Galzin
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 527-534;

  5. De Souza, E B

    1. Regulation of corticotropin-releasing factor-binding protein expression in cultured rat astrocytes.
      D Maciejewski, P D Crowe, E B De Souza and D P Behan
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 455-461;

  6. Devaud, L L

    1. Sensitization of gamma-aminobutyric acidA receptors to neuroactive steroids in rats during ethanol withdrawal.
      L L Devaud, R H Purdy, D A Finn and A L Morrow
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 510-517;

  7. Diao, L

    1. Interactions between ethanol, endogenous adenosine and adenosine uptake in hippocampal brain slices.
      L Diao and T V Dunwiddie
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 542-546;

  8. Dingledine, R

    1. Block of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors by polyamines and polyamine toxins.
      M S Washburn and R Dingledine
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 669-678;

  9. Dunnick, C A

    1. Mechanism mediating basolateral transport of 2,4-dichlorophenoxyacetic acid in rat kidney.
      A R Villalobos, C A Dunnick and J B Pritchard
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 582-589;

  10. Dunwiddie, T V

    1. Interactions between ethanol, endogenous adenosine and adenosine uptake in hippocampal brain slices.
      L Diao and T V Dunwiddie
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 542-546;

E

  1. Egawa, M

    1. Novel benzodioxan derivative, 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl) amino]propoxy]-1,3-benzodioxole HCl (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models.
      M Abe, R Tabata, K Saito, T Matsuda, A Baba and M Egawa
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 898-905;

  2. Eikenburg, D C

    1. Prejunctional alpha adrenoceptor desensitization in rat heart after chronic epinephrine treatment.
      S Apparsundaram and D C Eikenburg
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 862-870;

  3. Ellis, D B

    1. Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity.
      A M Szczepanik, L R Brougham, J E Roehr, P G Conway, D B Ellis and C A Wilmot
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 913-920;

  4. Ellis, J L

    1. Inhibition by zinc protoporphyrin-IX of vasoactive intestinal peptide-induced relaxations of guinea pig isolated trachea.
      B J Undem, J L Ellis, S Meeker, A Fischer and B J Canning
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 964-970;

  5. Ellis, S B

    1. Cloning and functional characterization of human heteromeric N-methyl-D-aspartate receptors.
      S D Hess, L P Daggett, J Crona, C Deal, C C Lu, A Urrutia, L Chavez-Noriega, S B Ellis, E C Johnson and G Veliçelebi
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 808-816;

F

  1. Feinmark, S J

    1. Phospholipase D activity regulates the binding of leukotriene B4 to human polymorphonuclear leukocytes.
      D Kiel and S J Feinmark
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 645-653;

  2. Feng, Z

    1. Leukotriene B4 modulates in vivo expression of delayed-type hypersensitivity by a receptor-mediated mechanism: regulation by lipoxin A4.
      Z Feng, H P Godfrey, S Mandy, S Strudwick, K T Lin, E Heilman and P Y Wong
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 950-956;

  3. Ferrara, P

    1. Characterization of two cloned human CB1 cannabinoid receptor isoforms.
      M Rinaldi-Carmona, B Calandra, D Shire, M Bouaboula, D Oustric, F Barth, P Casellas, P Ferrara and G Le Fur
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 871-878;

  4. Feurle, G E

    1. Neurokinetic and myokinetic effects of the peptide xenin on the motility of the small and large intestine of guinea pig.
      G E Feurle, A Klein, G Hamscher, J W Metzger and J A Schuurkes
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 654-661;

  5. Finn, D A

    1. Sensitization of gamma-aminobutyric acidA receptors to neuroactive steroids in rats during ethanol withdrawal.
      L L Devaud, R H Purdy, D A Finn and A L Morrow
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 510-517;

  6. Fischer, A

    1. Inhibition by zinc protoporphyrin-IX of vasoactive intestinal peptide-induced relaxations of guinea pig isolated trachea.
      B J Undem, J L Ellis, S Meeker, A Fischer and B J Canning
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 964-970;

  7. Fleshner, M R

    1. Morphine-induced alterations in antibody levels: receptor and immune mechanisms.
      L L Lockwood, L H Silbert, M R Fleshner, C McNeal, L R Watkins, M L Laudenslager, K C Rice, R J Weber and S F Maier
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 689-696;

  8. Floreani, M

    1. Mechanisms of plumbagin action on guinea pig isolated atria.
      M Floreani, A Forlin, L Pandolfo, M Petrone and S Bellin
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 763-770;

  9. Forlin, A

    1. Mechanisms of plumbagin action on guinea pig isolated atria.
      M Floreani, A Forlin, L Pandolfo, M Petrone and S Bellin
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 763-770;

  10. Fornal, C A

    1. WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135.
      C A Fornal, C W Metzler, R A Gallegos, S C Veasey, A C McCreary and B L Jacobs
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 752-762;

  11. Fournié-Zaluski, M C

    1. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
      W Gonzalez, F Beslot, I Laboulandine, M C Fournié-Zaluski, B P Roques and J B Michel
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 573-581;

  12. Fraser, D J

    1. Escherichia coli expression and substrate specificities of canine cytochrome P450 3A12 and rabbit cytochrome P450 3A6.
      S L Born, D J Fraser, G R Harlow and J R Halpert
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 957-963;

  13. Fuh, S M

    1. Locally application of amphetamine into the ventral tegmental area enhances dopamine release in the nucleus accumbens and the medial prefrontal cortex through noradrenergic neurotransmission.
      W H Pan, J C Sung and S M Fuh
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 725-731;

  14. Fukami, T

    1. Carrier-mediated active transport of BQ-123, a peptidic endothelin antagonist, into rat hepatocytes.
      T Nakamura, A Hisaka, Y Sawasaki, Y Suzuki, T Fukami, K Ishikawa, M Yano and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 564-572;

  15. Fulton, D

    1. Role of phospholipase C and phospholipase A2 in the nitric oxide-independent vasodilator effect of bradykinin in the rat perfused heart.
      D Fulton, J C McGiff and J Quilley
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 518-526;

G

  1. Gallegos, R A

    1. WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135.
      C A Fornal, C W Metzler, R A Gallegos, S C Veasey, A C McCreary and B L Jacobs
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 752-762;

  2. Gálvez, J

    1. Effect of quercitrin on acute and chronic experimental colitis in the rat.
      F Sánchez de Medina, J Gálvez, J A Romero and A Zarzuelo
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 771-779;

  3. Galzin, A M

    1. Functional characterization of alpha-1-adrenoceptor subtypes in the prostatic urethra and trigone of male rabbit.
      V Deplanne and A M Galzin
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 527-534;

  4. Gater, P R

    1. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways.
      L M Renzetti, P M Paciorek, S A Tannu, N C Rinaldi, J E Tocker, M A Wasserman and P R Gater
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 847-853;

  5. Gent, J P

    1. gamma-Aminobutyric acidA receptors and spinally mediated antinociception in rats.
      R Nadeson, Z Guo, V Porter, J P Gent and C S Goodchild
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 620-626;

  6. Gerthoffer, W T

    1. Agonist synergism in airway smooth muscle contraction.
      W T Gerthoffer
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 800-807;

  7. Gibb, J W

    1. Microdialysis assessment of methamphetamine-induced changes in extracellular neurotensin in the striatum and nucleus accumbens.
      J D Wagstaff, J W Gibb and G R Hanson
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 547-554;

  8. Godfrey, H P

    1. Leukotriene B4 modulates in vivo expression of delayed-type hypersensitivity by a receptor-mediated mechanism: regulation by lipoxin A4.
      Z Feng, H P Godfrey, S Mandy, S Strudwick, K T Lin, E Heilman and P Y Wong
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 950-956;

  9. Golub, M S

    1. Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation.
      M D Nyby, M Sasaki, Y Ideguchi, H E Wynne, M T Hori, M E Berger, M S Golub, A S Brickman and M L Tuck
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 503-509;

  10. Gonzalez, W

    1. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
      W Gonzalez, F Beslot, I Laboulandine, M C Fournié-Zaluski, B P Roques and J B Michel
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 573-581;

  11. Goodchild, C S

    1. gamma-Aminobutyric acidA receptors and spinally mediated antinociception in rats.
      R Nadeson, Z Guo, V Porter, J P Gent and C S Goodchild
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 620-626;

  12. Guo, Z

    1. gamma-Aminobutyric acidA receptors and spinally mediated antinociception in rats.
      R Nadeson, Z Guo, V Porter, J P Gent and C S Goodchild
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 620-626;

H

  1. Halpert, J R

    1. Escherichia coli expression and substrate specificities of canine cytochrome P450 3A12 and rabbit cytochrome P450 3A6.
      S L Born, D J Fraser, G R Harlow and J R Halpert
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 957-963;

  2. Hamon, M

    1. Electrophysiological effects of N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl) cyclohexane carboxamide (WAY 100635) on dorsal raphe serotonergic neurons and CA1 hippocampal pyramidal cells in vitro.
      R Corradetti, E Le Poul, N Laaris, M Hamon and L Lanfumey
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 679-688;

  3. Hamscher, G

    1. Neurokinetic and myokinetic effects of the peptide xenin on the motility of the small and large intestine of guinea pig.
      G E Feurle, A Klein, G Hamscher, J W Metzger and J A Schuurkes
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 654-661;

  4. Hanson, G R

    1. Microdialysis assessment of methamphetamine-induced changes in extracellular neurotensin in the striatum and nucleus accumbens.
      J D Wagstaff, J W Gibb and G R Hanson
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 547-554;

  5. Harlow, G R

    1. Escherichia coli expression and substrate specificities of canine cytochrome P450 3A12 and rabbit cytochrome P450 3A6.
      S L Born, D J Fraser, G R Harlow and J R Halpert
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 957-963;

  6. Heidbreder, C A

    1. Role of extracellular dopamine in the initiation and long-term expression of behavioral sensitization to cocaine.
      C A Heidbreder, A C Thompson and T S Shippenberg
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 490-502;

  7. Heilman, E

    1. Leukotriene B4 modulates in vivo expression of delayed-type hypersensitivity by a receptor-mediated mechanism: regulation by lipoxin A4.
      Z Feng, H P Godfrey, S Mandy, S Strudwick, K T Lin, E Heilman and P Y Wong
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 950-956;

  8. Henmi, S

    1. Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle.
      K Muraki, H Nakagawa, N Nagano, S Henmi, H Kawasumi, T Nakanishi, K Imaizumi, T Tokuno, K Atsuki, Y Imaizumi and M Watanabe
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 555-563;

  9. Hess, S D

    1. Cloning and functional characterization of human heteromeric N-methyl-D-aspartate receptors.
      S D Hess, L P Daggett, J Crona, C Deal, C C Lu, A Urrutia, L Chavez-Noriega, S B Ellis, E C Johnson and G Veliçelebi
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 808-816;

  10. Hinz, V C

    1. Effects of metrifonate, its transformation product dichlorvos, and other organophosphorus and reference cholinesterase inhibitors on Morris water escape behavior in young-adult rats.
      F J van der Staay, V C Hinz and B H Schmidt
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 697-708;

  11. Hisaka, A

    1. Carrier-mediated active transport of BQ-123, a peptidic endothelin antagonist, into rat hepatocytes.
      T Nakamura, A Hisaka, Y Sawasaki, Y Suzuki, T Fukami, K Ishikawa, M Yano and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 564-572;
    2. The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123.
      H C Shin, Y Kato, Y Shitara, T Yamada, T Nakamura, A Hisaka and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 607-613;

  12. Hoffmann, I S

    1. Differential effects of muscarinic receptor agonists and phorbol ester on muscarinic and D2-dopamine release-modulatory receptors.
      I S Hoffmann, R K Talmaciu, R Aquino and L X Cubeddu
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 662-668;

  13. Hong, C Y

    1. Vascular hyporesponsiveness in aorta from portal hypertensive rats: possible sites of involvement.
      Y T Huang, G F Wang, M C Yang, S P Chang, H C Lin and C Y Hong
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 535-541;

  14. Hori, M

    1. A nitric oxide donor reverses myocardial injury in rabbits with acute hypercholesterolemia.
      S Hoshida, N Yamashita, J Igarashi, M Nishida, M Hori, T Kuzuya and M Tada
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 741-746;

  15. Hori, M T

    1. Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation.
      M D Nyby, M Sasaki, Y Ideguchi, H E Wynne, M T Hori, M E Berger, M S Golub, A S Brickman and M L Tuck
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 503-509;

  16. Hoshida, S

    1. A nitric oxide donor reverses myocardial injury in rabbits with acute hypercholesterolemia.
      S Hoshida, N Yamashita, J Igarashi, M Nishida, M Hori, T Kuzuya and M Tada
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 741-746;

  17. Huang, Y T

    1. Vascular hyporesponsiveness in aorta from portal hypertensive rats: possible sites of involvement.
      Y T Huang, G F Wang, M C Yang, S P Chang, H C Lin and C Y Hong
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 535-541;

I

  1. Ideguchi, Y

    1. Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation.
      M D Nyby, M Sasaki, Y Ideguchi, H E Wynne, M T Hori, M E Berger, M S Golub, A S Brickman and M L Tuck
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 503-509;

  2. Igarashi, J

    1. A nitric oxide donor reverses myocardial injury in rabbits with acute hypercholesterolemia.
      S Hoshida, N Yamashita, J Igarashi, M Nishida, M Hori, T Kuzuya and M Tada
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 741-746;

  3. Iino, T

    1. Effect of vinconate, an indolonaphthyridine derivative, on dopamine and serotonin concentrations in dialysate from the striatum of freely moving rats: brain microdialysis studies.
      T Iino, M Katsura and K Kuriyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 614-619;

  4. Imaizumi, K

    1. Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle.
      K Muraki, H Nakagawa, N Nagano, S Henmi, H Kawasumi, T Nakanishi, K Imaizumi, T Tokuno, K Atsuki, Y Imaizumi and M Watanabe
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 555-563;

  5. Imaizumi, Y

    1. Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle.
      K Muraki, H Nakagawa, N Nagano, S Henmi, H Kawasumi, T Nakanishi, K Imaizumi, T Tokuno, K Atsuki, Y Imaizumi and M Watanabe
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 555-563;

  6. Imamura, H

    1. Mechanism of stereoselective serum binding of ketoprofen after hemodialysis.
      T Sakai, T Maruyama, H Imamura, H Shimada and M Otagiri
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 786-792;

  7. Ishikawa, K

    1. Carrier-mediated active transport of BQ-123, a peptidic endothelin antagonist, into rat hepatocytes.
      T Nakamura, A Hisaka, Y Sawasaki, Y Suzuki, T Fukami, K Ishikawa, M Yano and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 564-572;

  8. Iyer, R P

    1. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration.
      R Zhang, R P Iyer, D Yu, W Tan, X Zhang, Z Lu, H Zhao and S Agrawal
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 971-979;

J

  1. Jacobs, B L

    1. WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135.
      C A Fornal, C W Metzler, R A Gallegos, S C Veasey, A C McCreary and B L Jacobs
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 752-762;

  2. Jeannin, J F

    1. Immunomodulator OM 163-induced reversal of tumor-mediated immunosuppression and downregulation of TGF-beta 1 in vivo.
      P Lagadec, S Reveneau, P Lejeune, D Pinard, T Borman, J Bauer and J F Jeannin
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 926-933;

  3. Johnson, E C

    1. Cloning and functional characterization of human heteromeric N-methyl-D-aspartate receptors.
      S D Hess, L P Daggett, J Crona, C Deal, C C Lu, A Urrutia, L Chavez-Noriega, S B Ellis, E C Johnson and G Veliçelebi
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 808-816;

K

  1. Kan, H

    1. Modulation by cyclic AMP of beta adrenergic receptor-stimulated prostacyclin synthesis in rabbit ventricular myocytes.
      Y Ruan, H Kan and K U Malik
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 482-489;

  2. Kato, Y

    1. The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123.
      H C Shin, Y Kato, Y Shitara, T Yamada, T Nakamura, A Hisaka and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 607-613;

  3. Katsura, M

    1. Effect of vinconate, an indolonaphthyridine derivative, on dopamine and serotonin concentrations in dialysate from the striatum of freely moving rats: brain microdialysis studies.
      T Iino, M Katsura and K Kuriyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 614-619;

  4. Kawai, H

    1. Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model.
      H Kawai, S Yuki, J Sugimoto and Y Tamao
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 780-785;

  5. Kawanishi, T

    1. Use of chloride blockers: a novel approach for cardioprotection against ischemia-reperfusion damage.
      H Tanaka, S Matsui, T Kawanishi and K Shigenobu
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 854-861;

  6. Kawasumi, H

    1. Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle.
      K Muraki, H Nakagawa, N Nagano, S Henmi, H Kawasumi, T Nakanishi, K Imaizumi, T Tokuno, K Atsuki, Y Imaizumi and M Watanabe
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 555-563;

  7. Kessler, M

    1. Effects of a memory-enhancing drug on DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus.
      A Arai, M Kessler, G Rogers and G Lynch
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 627-638;

  8. Kiel, D

    1. Phospholipase D activity regulates the binding of leukotriene B4 to human polymorphonuclear leukocytes.
      D Kiel and S J Feinmark
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 645-653;

  9. Klapper, L

    1. Thrombin stimulates atrial natriuretic peptide secretion from rat cardiac atrium.
      L Klapper, S Nachshon, O Zamir and N Zamir
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 476-481;

  10. Klein, A

    1. Neurokinetic and myokinetic effects of the peptide xenin on the motility of the small and large intestine of guinea pig.
      G E Feurle, A Klein, G Hamscher, J W Metzger and J A Schuurkes
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 654-661;

  11. Kuriyama, K

    1. Effect of vinconate, an indolonaphthyridine derivative, on dopamine and serotonin concentrations in dialysate from the striatum of freely moving rats: brain microdialysis studies.
      T Iino, M Katsura and K Kuriyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 614-619;

  12. Kuzuya, T

    1. A nitric oxide donor reverses myocardial injury in rabbits with acute hypercholesterolemia.
      S Hoshida, N Yamashita, J Igarashi, M Nishida, M Hori, T Kuzuya and M Tada
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 741-746;

L

  1. Laaris, N

    1. Electrophysiological effects of N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl) cyclohexane carboxamide (WAY 100635) on dorsal raphe serotonergic neurons and CA1 hippocampal pyramidal cells in vitro.
      R Corradetti, E Le Poul, N Laaris, M Hamon and L Lanfumey
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 679-688;

  2. Laboulandine, I

    1. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
      W Gonzalez, F Beslot, I Laboulandine, M C Fournié-Zaluski, B P Roques and J B Michel
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 573-581;

  3. Lagadec, P

    1. Immunomodulator OM 163-induced reversal of tumor-mediated immunosuppression and downregulation of TGF-beta 1 in vivo.
      P Lagadec, S Reveneau, P Lejeune, D Pinard, T Borman, J Bauer and J F Jeannin
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 926-933;

  4. Lamas, X

    1. Acute and chronic effects of flupenthixol on the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys.
      S S Negus, N K Mello, X Lamas and J H Mendelson
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 879-890;

  5. Lanfumey, L

    1. Electrophysiological effects of N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl) cyclohexane carboxamide (WAY 100635) on dorsal raphe serotonergic neurons and CA1 hippocampal pyramidal cells in vitro.
      R Corradetti, E Le Poul, N Laaris, M Hamon and L Lanfumey
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 679-688;

  6. Laudenslager, M L

    1. Morphine-induced alterations in antibody levels: receptor and immune mechanisms.
      L L Lockwood, L H Silbert, M R Fleshner, C McNeal, L R Watkins, M L Laudenslager, K C Rice, R J Weber and S F Maier
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 689-696;

  7. Lee, H C

    1. Mechanism of alpha-2 adrenergic modulation of canine cardiac Purkinje action potential.
      H C Lee, J J Cai, D O Arnar, E F Shibata and J B Martins
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 597-606;

  8. Le Fur, G

    1. Characterization of two cloned human CB1 cannabinoid receptor isoforms.
      M Rinaldi-Carmona, B Calandra, D Shire, M Bouaboula, D Oustric, F Barth, P Casellas, P Ferrara and G Le Fur
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 871-878;

  9. Lejeune, P

    1. Immunomodulator OM 163-induced reversal of tumor-mediated immunosuppression and downregulation of TGF-beta 1 in vivo.
      P Lagadec, S Reveneau, P Lejeune, D Pinard, T Borman, J Bauer and J F Jeannin
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 926-933;

  10. Le Poul, E

    1. Electrophysiological effects of N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl) cyclohexane carboxamide (WAY 100635) on dorsal raphe serotonergic neurons and CA1 hippocampal pyramidal cells in vitro.
      R Corradetti, E Le Poul, N Laaris, M Hamon and L Lanfumey
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 679-688;

  11. Limberger, N

    1. The presynaptic alpha-2 autoreceptors in pig brain cortex are alpha-2A.
      A U Trendelenburg, N Limberger and K Starke
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 462-467;

  12. Lin, H C

    1. Vascular hyporesponsiveness in aorta from portal hypertensive rats: possible sites of involvement.
      Y T Huang, G F Wang, M C Yang, S P Chang, H C Lin and C Y Hong
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 535-541;

  13. Lin, K T

    1. Leukotriene B4 modulates in vivo expression of delayed-type hypersensitivity by a receptor-mediated mechanism: regulation by lipoxin A4.
      Z Feng, H P Godfrey, S Mandy, S Strudwick, K T Lin, E Heilman and P Y Wong
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 950-956;

  14. Lockwood, L L

    1. Morphine-induced alterations in antibody levels: receptor and immune mechanisms.
      L L Lockwood, L H Silbert, M R Fleshner, C McNeal, L R Watkins, M L Laudenslager, K C Rice, R J Weber and S F Maier
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 689-696;

  15. Lovinger, D M

    1. Pharmacologic characteristics of potentiation of 5-HT3 receptors by alcohols and diethyl ether in NCB-20 neuroblastoma cells.
      Q Zhou and D M Lovinger
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 732-740;

  16. Lu, C C

    1. Cloning and functional characterization of human heteromeric N-methyl-D-aspartate receptors.
      S D Hess, L P Daggett, J Crona, C Deal, C C Lu, A Urrutia, L Chavez-Noriega, S B Ellis, E C Johnson and G Veliçelebi
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 808-816;

  17. Lu, Z

    1. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration.
      R Zhang, R P Iyer, D Yu, W Tan, X Zhang, Z Lu, H Zhao and S Agrawal
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 971-979;

  18. Luquita, M G

    1. Ovine prolactin increases hepatic UDP-glucuronosyltransferase activity in ovariectomized rats.
      M G Luquita, V A Catania, E J Sánchez-Pozzi and A D Mottino
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 921-925;

  19. Lynch, G

    1. Effects of a memory-enhancing drug on DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus.
      A Arai, M Kessler, G Rogers and G Lynch
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 627-638;

M

  1. Maciejewski, D

    1. Regulation of corticotropin-releasing factor-binding protein expression in cultured rat astrocytes.
      D Maciejewski, P D Crowe, E B De Souza and D P Behan
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 455-461;

  2. Macrez-Leprêtre, N

    1. Angiotensin II-mediated activation of L-type calcium channels involves phosphatidylinositol hydrolysis-independent activation of protein kinase C in rat portal vein myocytes.
      N Macrez-Leprêtre, J L Morel and J Mironneau
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 468-475;

  3. Maier, S F

    1. Morphine-induced alterations in antibody levels: receptor and immune mechanisms.
      L L Lockwood, L H Silbert, M R Fleshner, C McNeal, L R Watkins, M L Laudenslager, K C Rice, R J Weber and S F Maier
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 689-696;

  4. Malik, K U

    1. Modulation by cyclic AMP of beta adrenergic receptor-stimulated prostacyclin synthesis in rabbit ventricular myocytes.
      Y Ruan, H Kan and K U Malik
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 482-489;

  5. Mandy, S

    1. Leukotriene B4 modulates in vivo expression of delayed-type hypersensitivity by a receptor-mediated mechanism: regulation by lipoxin A4.
      Z Feng, H P Godfrey, S Mandy, S Strudwick, K T Lin, E Heilman and P Y Wong
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 950-956;

  6. Martins, J B

    1. Mechanism of alpha-2 adrenergic modulation of canine cardiac Purkinje action potential.
      H C Lee, J J Cai, D O Arnar, E F Shibata and J B Martins
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 597-606;

  7. Maruyama, T

    1. Mechanism of stereoselective serum binding of ketoprofen after hemodialysis.
      T Sakai, T Maruyama, H Imamura, H Shimada and M Otagiri
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 786-792;

  8. Matsuda, T

    1. Novel benzodioxan derivative, 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl) amino]propoxy]-1,3-benzodioxole HCl (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models.
      M Abe, R Tabata, K Saito, T Matsuda, A Baba and M Egawa
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 898-905;

  9. Matsui, S

    1. Use of chloride blockers: a novel approach for cardioprotection against ischemia-reperfusion damage.
      H Tanaka, S Matsui, T Kawanishi and K Shigenobu
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 854-861;

  10. Matsuoka, N

    1. D-cycloserine, a partial agonist at the glycine site coupled to N-methyl-D-aspartate receptors, improves visual recognition memory in rhesus monkeys.
      N Matsuoka and T G Aigner
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 891-897;

  11. Mayersohn, M

    1. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats.
      J L Valentine, M Mayersohn, W D Wessinger, L W Arnold and S M Owens
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 709-716;

  12. McCreary, A C

    1. WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135.
      C A Fornal, C W Metzler, R A Gallegos, S C Veasey, A C McCreary and B L Jacobs
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 752-762;

  13. McGiff, J C

    1. Role of phospholipase C and phospholipase A2 in the nitric oxide-independent vasodilator effect of bradykinin in the rat perfused heart.
      D Fulton, J C McGiff and J Quilley
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 518-526;

  14. McNeal, C

    1. Morphine-induced alterations in antibody levels: receptor and immune mechanisms.
      L L Lockwood, L H Silbert, M R Fleshner, C McNeal, L R Watkins, M L Laudenslager, K C Rice, R J Weber and S F Maier
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 689-696;

  15. Meeker, S

    1. Inhibition by zinc protoporphyrin-IX of vasoactive intestinal peptide-induced relaxations of guinea pig isolated trachea.
      B J Undem, J L Ellis, S Meeker, A Fischer and B J Canning
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 964-970;

  16. Mello, N K

    1. Acute and chronic effects of flupenthixol on the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys.
      S S Negus, N K Mello, X Lamas and J H Mendelson
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 879-890;

  17. Mendelson, J H

    1. Acute and chronic effects of flupenthixol on the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys.
      S S Negus, N K Mello, X Lamas and J H Mendelson
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 879-890;

  18. Metzger, J W

    1. Neurokinetic and myokinetic effects of the peptide xenin on the motility of the small and large intestine of guinea pig.
      G E Feurle, A Klein, G Hamscher, J W Metzger and J A Schuurkes
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 654-661;

  19. Metzger, W J

    1. Simultaneous measurement of cyclopentyladenosine-induced contraction and intracellular calcium in bronchial rings from allergic rabbits and it's antagonism.
      S Ali, W J Metzger and S J Mustafa
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 639-644;

  20. Metzler, C W

    1. WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135.
      C A Fornal, C W Metzler, R A Gallegos, S C Veasey, A C McCreary and B L Jacobs
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 752-762;

  21. Michel, J B

    1. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
      W Gonzalez, F Beslot, I Laboulandine, M C Fournié-Zaluski, B P Roques and J B Michel
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 573-581;

  22. Mironneau, J

    1. Angiotensin II-mediated activation of L-type calcium channels involves phosphatidylinositol hydrolysis-independent activation of protein kinase C in rat portal vein myocytes.
      N Macrez-Leprêtre, J L Morel and J Mironneau
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 468-475;

  23. Morais, R

    1. Chloramphenicol and the inflammatory response in the rat. Upregulation of the gene for T2-kininogen in liver.
      P Raymond, H Wang, C Blais, A Décarie, A Adam and R Morais
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 934-940;

  24. Morel, J L

    1. Angiotensin II-mediated activation of L-type calcium channels involves phosphatidylinositol hydrolysis-independent activation of protein kinase C in rat portal vein myocytes.
      N Macrez-Leprêtre, J L Morel and J Mironneau
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 468-475;

  25. Morrow, A L

    1. Sensitization of gamma-aminobutyric acidA receptors to neuroactive steroids in rats during ethanol withdrawal.
      L L Devaud, R H Purdy, D A Finn and A L Morrow
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 510-517;

  26. Mottino, A D

    1. Ovine prolactin increases hepatic UDP-glucuronosyltransferase activity in ovariectomized rats.
      M G Luquita, V A Catania, E J Sánchez-Pozzi and A D Mottino
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 921-925;

  27. Muraki, K

    1. Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle.
      K Muraki, H Nakagawa, N Nagano, S Henmi, H Kawasumi, T Nakanishi, K Imaizumi, T Tokuno, K Atsuki, Y Imaizumi and M Watanabe
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 555-563;

  28. Mustafa, S J

    1. Simultaneous measurement of cyclopentyladenosine-induced contraction and intracellular calcium in bronchial rings from allergic rabbits and it's antagonism.
      S Ali, W J Metzger and S J Mustafa
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 639-644;

N

  1. Nachshon, S

    1. Thrombin stimulates atrial natriuretic peptide secretion from rat cardiac atrium.
      L Klapper, S Nachshon, O Zamir and N Zamir
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 476-481;

  2. Nadeson, R

    1. gamma-Aminobutyric acidA receptors and spinally mediated antinociception in rats.
      R Nadeson, Z Guo, V Porter, J P Gent and C S Goodchild
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 620-626;

  3. Nagano, N

    1. Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle.
      K Muraki, H Nakagawa, N Nagano, S Henmi, H Kawasumi, T Nakanishi, K Imaizumi, T Tokuno, K Atsuki, Y Imaizumi and M Watanabe
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 555-563;

  4. Nakagawa, H

    1. Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle.
      K Muraki, H Nakagawa, N Nagano, S Henmi, H Kawasumi, T Nakanishi, K Imaizumi, T Tokuno, K Atsuki, Y Imaizumi and M Watanabe
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 555-563;

  5. Nakamura, T

    1. Carrier-mediated active transport of BQ-123, a peptidic endothelin antagonist, into rat hepatocytes.
      T Nakamura, A Hisaka, Y Sawasaki, Y Suzuki, T Fukami, K Ishikawa, M Yano and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 564-572;
    2. The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123.
      H C Shin, Y Kato, Y Shitara, T Yamada, T Nakamura, A Hisaka and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 607-613;

  6. Nakanishi, T

    1. Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle.
      K Muraki, H Nakagawa, N Nagano, S Henmi, H Kawasumi, T Nakanishi, K Imaizumi, T Tokuno, K Atsuki, Y Imaizumi and M Watanabe
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 555-563;

  7. Negus, S S

    1. Acute and chronic effects of flupenthixol on the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys.
      S S Negus, N K Mello, X Lamas and J H Mendelson
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 879-890;

  8. Nishida, M

    1. A nitric oxide donor reverses myocardial injury in rabbits with acute hypercholesterolemia.
      S Hoshida, N Yamashita, J Igarashi, M Nishida, M Hori, T Kuzuya and M Tada
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 741-746;

  9. Nyby, M D

    1. Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation.
      M D Nyby, M Sasaki, Y Ideguchi, H E Wynne, M T Hori, M E Berger, M S Golub, A S Brickman and M L Tuck
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 503-509;

O

  1. Olson, L

    1. A comparison of the effects of glial cell line-derived neurotrophic factor on spinal cord and cortex cerebri grafts.
      K Trok, S Almström and L Olson
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 941-949;

  2. Ooie, T

    1. Comparative distribution of quinolone antibiotics in cerebrospinal fluid and brain in rats and dogs.
      T Ooie, H Suzuki, T Terasaki and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 590-596;

  3. Otagiri, M

    1. Mechanism of stereoselective serum binding of ketoprofen after hemodialysis.
      T Sakai, T Maruyama, H Imamura, H Shimada and M Otagiri
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 786-792;

  4. Oustric, D

    1. Characterization of two cloned human CB1 cannabinoid receptor isoforms.
      M Rinaldi-Carmona, B Calandra, D Shire, M Bouaboula, D Oustric, F Barth, P Casellas, P Ferrara and G Le Fur
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 871-878;

  5. Owens, S M

    1. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats.
      J L Valentine, M Mayersohn, W D Wessinger, L W Arnold and S M Owens
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 709-716;
    2. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats.
      J L Valentine and S M Owens
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 717-724;

P

  1. Paciorek, P M

    1. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways.
      L M Renzetti, P M Paciorek, S A Tannu, N C Rinaldi, J E Tocker, M A Wasserman and P R Gater
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 847-853;

  2. Pan, W H

    1. Locally application of amphetamine into the ventral tegmental area enhances dopamine release in the nucleus accumbens and the medial prefrontal cortex through noradrenergic neurotransmission.
      W H Pan, J C Sung and S M Fuh
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 725-731;

  3. Pandolfo, L

    1. Mechanisms of plumbagin action on guinea pig isolated atria.
      M Floreani, A Forlin, L Pandolfo, M Petrone and S Bellin
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 763-770;

  4. Paudice, P

    1. Human brain cholecystokinin: release of cholecystokinin-like immunoreactivity (CCK-LI) from isolated cortical nerve endings and its modulation through GABA(B) receptors.
      M Raiteri, G Bonanno, P Paudice, P Cavazzani and G Schmid
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 747-751;

  5. Petrone, M

    1. Mechanisms of plumbagin action on guinea pig isolated atria.
      M Floreani, A Forlin, L Pandolfo, M Petrone and S Bellin
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 763-770;

  6. Pinard, D

    1. Immunomodulator OM 163-induced reversal of tumor-mediated immunosuppression and downregulation of TGF-beta 1 in vivo.
      P Lagadec, S Reveneau, P Lejeune, D Pinard, T Borman, J Bauer and J F Jeannin
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 926-933;

  7. Porter, V

    1. gamma-Aminobutyric acidA receptors and spinally mediated antinociception in rats.
      R Nadeson, Z Guo, V Porter, J P Gent and C S Goodchild
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 620-626;

  8. Preston, K L

    1. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans.
      K J Schuh, S L Walsh, G E Bigelow, K L Preston and M L Stitzer
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 836-846;

  9. Pritchard, J B

    1. Mechanism mediating basolateral transport of 2,4-dichlorophenoxyacetic acid in rat kidney.
      A R Villalobos, C A Dunnick and J B Pritchard
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 582-589;

  10. Purdy, R H

    1. Sensitization of gamma-aminobutyric acidA receptors to neuroactive steroids in rats during ethanol withdrawal.
      L L Devaud, R H Purdy, D A Finn and A L Morrow
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 510-517;

Q

  1. Quilley, J

    1. Role of phospholipase C and phospholipase A2 in the nitric oxide-independent vasodilator effect of bradykinin in the rat perfused heart.
      D Fulton, J C McGiff and J Quilley
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 518-526;

R

  1. Raiteri, M

    1. Human brain cholecystokinin: release of cholecystokinin-like immunoreactivity (CCK-LI) from isolated cortical nerve endings and its modulation through GABA(B) receptors.
      M Raiteri, G Bonanno, P Paudice, P Cavazzani and G Schmid
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 747-751;

  2. Raymond, P

    1. Chloramphenicol and the inflammatory response in the rat. Upregulation of the gene for T2-kininogen in liver.
      P Raymond, H Wang, C Blais, A Décarie, A Adam and R Morais
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 934-940;

  3. Reid, I A

    1. Role of cyclic GMP-inhibitable phosphodiesterase and nitric oxide in the beta adrenoceptor control of renin secretion.
      T Chiu and I A Reid
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 793-799;

  4. Renzetti, L M

    1. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways.
      L M Renzetti, P M Paciorek, S A Tannu, N C Rinaldi, J E Tocker, M A Wasserman and P R Gater
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 847-853;

  5. Reveneau, S

    1. Immunomodulator OM 163-induced reversal of tumor-mediated immunosuppression and downregulation of TGF-beta 1 in vivo.
      P Lagadec, S Reveneau, P Lejeune, D Pinard, T Borman, J Bauer and J F Jeannin
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 926-933;

  6. Rice, K C

    1. Morphine-induced alterations in antibody levels: receptor and immune mechanisms.
      L L Lockwood, L H Silbert, M R Fleshner, C McNeal, L R Watkins, M L Laudenslager, K C Rice, R J Weber and S F Maier
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 689-696;

  7. Rinaldi, N C

    1. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways.
      L M Renzetti, P M Paciorek, S A Tannu, N C Rinaldi, J E Tocker, M A Wasserman and P R Gater
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 847-853;

  8. Rinaldi-Carmona, M

    1. Characterization of two cloned human CB1 cannabinoid receptor isoforms.
      M Rinaldi-Carmona, B Calandra, D Shire, M Bouaboula, D Oustric, F Barth, P Casellas, P Ferrara and G Le Fur
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 871-878;

  9. Roehr, J E

    1. Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity.
      A M Szczepanik, L R Brougham, J E Roehr, P G Conway, D B Ellis and C A Wilmot
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 913-920;

  10. Rogers, G

    1. Effects of a memory-enhancing drug on DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus.
      A Arai, M Kessler, G Rogers and G Lynch
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 627-638;

  11. Romero, J A

    1. Effect of quercitrin on acute and chronic experimental colitis in the rat.
      F Sánchez de Medina, J Gálvez, J A Romero and A Zarzuelo
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 771-779;

  12. Roques, B P

    1. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
      W Gonzalez, F Beslot, I Laboulandine, M C Fournié-Zaluski, B P Roques and J B Michel
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 573-581;

  13. Rosen, M R

    1. Chronic in vivo and in vitro effects of amiodarone on guinea pig hearts.
      E A Sosunov, E P Anyukhovsky and M R Rosen
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 906-912;

  14. Ruan, Y

    1. Modulation by cyclic AMP of beta adrenergic receptor-stimulated prostacyclin synthesis in rabbit ventricular myocytes.
      Y Ruan, H Kan and K U Malik
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 482-489;

S

  1. Saito, K

    1. Novel benzodioxan derivative, 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl) amino]propoxy]-1,3-benzodioxole HCl (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models.
      M Abe, R Tabata, K Saito, T Matsuda, A Baba and M Egawa
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 898-905;

  2. Sakai, T

    1. Mechanism of stereoselective serum binding of ketoprofen after hemodialysis.
      T Sakai, T Maruyama, H Imamura, H Shimada and M Otagiri
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 786-792;

  3. Sánchez-Pozzi, E J

    1. Ovine prolactin increases hepatic UDP-glucuronosyltransferase activity in ovariectomized rats.
      M G Luquita, V A Catania, E J Sánchez-Pozzi and A D Mottino
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 921-925;

  4. Sánchez de Medina, F

    1. Effect of quercitrin on acute and chronic experimental colitis in the rat.
      F Sánchez de Medina, J Gálvez, J A Romero and A Zarzuelo
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 771-779;

  5. Sasaki, M

    1. Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation.
      M D Nyby, M Sasaki, Y Ideguchi, H E Wynne, M T Hori, M E Berger, M S Golub, A S Brickman and M L Tuck
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 503-509;

  6. Satoh, H

    1. Ca(++)-dependence of caffeine modulation of the rate-force relation in canine cardiac Purkinje fibers.
      H Satoh and M Vassalle
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 826-835;

  7. Sawasaki, Y

    1. Carrier-mediated active transport of BQ-123, a peptidic endothelin antagonist, into rat hepatocytes.
      T Nakamura, A Hisaka, Y Sawasaki, Y Suzuki, T Fukami, K Ishikawa, M Yano and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 564-572;

  8. Schmid, G

    1. Human brain cholecystokinin: release of cholecystokinin-like immunoreactivity (CCK-LI) from isolated cortical nerve endings and its modulation through GABA(B) receptors.
      M Raiteri, G Bonanno, P Paudice, P Cavazzani and G Schmid
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 747-751;

  9. Schmidt, B H

    1. Effects of metrifonate, its transformation product dichlorvos, and other organophosphorus and reference cholinesterase inhibitors on Morris water escape behavior in young-adult rats.
      F J van der Staay, V C Hinz and B H Schmidt
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 697-708;

  10. Schuh, K J

    1. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans.
      K J Schuh, S L Walsh, G E Bigelow, K L Preston and M L Stitzer
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 836-846;

  11. Schuurkes, J A

    1. Neurokinetic and myokinetic effects of the peptide xenin on the motility of the small and large intestine of guinea pig.
      G E Feurle, A Klein, G Hamscher, J W Metzger and J A Schuurkes
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 654-661;

  12. Scott, M

    1. Morphine suppresses the alloantigen-driven CTL response in a dose-dependent and naltrexone reversible manner.
      M Scott and D J Carr
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 980-988;

  13. Shibata, E F

    1. Mechanism of alpha-2 adrenergic modulation of canine cardiac Purkinje action potential.
      H C Lee, J J Cai, D O Arnar, E F Shibata and J B Martins
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 597-606;

  14. Shigenobu, K

    1. Use of chloride blockers: a novel approach for cardioprotection against ischemia-reperfusion damage.
      H Tanaka, S Matsui, T Kawanishi and K Shigenobu
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 854-861;

  15. Shimada, H

    1. Mechanism of stereoselective serum binding of ketoprofen after hemodialysis.
      T Sakai, T Maruyama, H Imamura, H Shimada and M Otagiri
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 786-792;

  16. Shin, H C

    1. The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123.
      H C Shin, Y Kato, Y Shitara, T Yamada, T Nakamura, A Hisaka and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 607-613;

  17. Shippenberg, T S

    1. Role of extracellular dopamine in the initiation and long-term expression of behavioral sensitization to cocaine.
      C A Heidbreder, A C Thompson and T S Shippenberg
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 490-502;

  18. Shire, D

    1. Characterization of two cloned human CB1 cannabinoid receptor isoforms.
      M Rinaldi-Carmona, B Calandra, D Shire, M Bouaboula, D Oustric, F Barth, P Casellas, P Ferrara and G Le Fur
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 871-878;

  19. Shitara, Y

    1. The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123.
      H C Shin, Y Kato, Y Shitara, T Yamada, T Nakamura, A Hisaka and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 607-613;

  20. Silbert, L H

    1. Morphine-induced alterations in antibody levels: receptor and immune mechanisms.
      L L Lockwood, L H Silbert, M R Fleshner, C McNeal, L R Watkins, M L Laudenslager, K C Rice, R J Weber and S F Maier
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 689-696;

  21. Skerjanec, A

    1. Mechanisms of nonlinear pharmacokinetics of mibefradil in chronically instrumented dogs.
      A Skerjanec, S Tawfik and Y K Tam
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 817-825;

  22. Sosunov, E A

    1. Chronic in vivo and in vitro effects of amiodarone on guinea pig hearts.
      E A Sosunov, E P Anyukhovsky and M R Rosen
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 906-912;

  23. Starke, K

    1. The presynaptic alpha-2 autoreceptors in pig brain cortex are alpha-2A.
      A U Trendelenburg, N Limberger and K Starke
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 462-467;

  24. Stitzer, M L

    1. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans.
      K J Schuh, S L Walsh, G E Bigelow, K L Preston and M L Stitzer
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 836-846;

  25. Strudwick, S

    1. Leukotriene B4 modulates in vivo expression of delayed-type hypersensitivity by a receptor-mediated mechanism: regulation by lipoxin A4.
      Z Feng, H P Godfrey, S Mandy, S Strudwick, K T Lin, E Heilman and P Y Wong
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 950-956;

  26. Sugimoto, J

    1. Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model.
      H Kawai, S Yuki, J Sugimoto and Y Tamao
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 780-785;

  27. Sugiyama, Y

    1. Carrier-mediated active transport of BQ-123, a peptidic endothelin antagonist, into rat hepatocytes.
      T Nakamura, A Hisaka, Y Sawasaki, Y Suzuki, T Fukami, K Ishikawa, M Yano and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 564-572;
    2. Comparative distribution of quinolone antibiotics in cerebrospinal fluid and brain in rats and dogs.
      T Ooie, H Suzuki, T Terasaki and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 590-596;
    3. The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123.
      H C Shin, Y Kato, Y Shitara, T Yamada, T Nakamura, A Hisaka and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 607-613;

  28. Sung, J C

    1. Locally application of amphetamine into the ventral tegmental area enhances dopamine release in the nucleus accumbens and the medial prefrontal cortex through noradrenergic neurotransmission.
      W H Pan, J C Sung and S M Fuh
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 725-731;

  29. Suzuki, H

    1. Comparative distribution of quinolone antibiotics in cerebrospinal fluid and brain in rats and dogs.
      T Ooie, H Suzuki, T Terasaki and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 590-596;

  30. Suzuki, Y

    1. Carrier-mediated active transport of BQ-123, a peptidic endothelin antagonist, into rat hepatocytes.
      T Nakamura, A Hisaka, Y Sawasaki, Y Suzuki, T Fukami, K Ishikawa, M Yano and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 564-572;

  31. Szczepanik, A M

    1. Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity.
      A M Szczepanik, L R Brougham, J E Roehr, P G Conway, D B Ellis and C A Wilmot
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 913-920;

T

  1. Tabata, R

    1. Novel benzodioxan derivative, 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl) amino]propoxy]-1,3-benzodioxole HCl (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models.
      M Abe, R Tabata, K Saito, T Matsuda, A Baba and M Egawa
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 898-905;

  2. Tada, M

    1. A nitric oxide donor reverses myocardial injury in rabbits with acute hypercholesterolemia.
      S Hoshida, N Yamashita, J Igarashi, M Nishida, M Hori, T Kuzuya and M Tada
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 741-746;

  3. Talmaciu, R K

    1. Differential effects of muscarinic receptor agonists and phorbol ester on muscarinic and D2-dopamine release-modulatory receptors.
      I S Hoffmann, R K Talmaciu, R Aquino and L X Cubeddu
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 662-668;

  4. Tam, Y K

    1. Mechanisms of nonlinear pharmacokinetics of mibefradil in chronically instrumented dogs.
      A Skerjanec, S Tawfik and Y K Tam
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 817-825;

  5. Tamao, Y

    1. Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model.
      H Kawai, S Yuki, J Sugimoto and Y Tamao
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 780-785;

  6. Tan, W

    1. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration.
      R Zhang, R P Iyer, D Yu, W Tan, X Zhang, Z Lu, H Zhao and S Agrawal
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 971-979;

  7. Tanaka, H

    1. Use of chloride blockers: a novel approach for cardioprotection against ischemia-reperfusion damage.
      H Tanaka, S Matsui, T Kawanishi and K Shigenobu
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 854-861;

  8. Tannu, S A

    1. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways.
      L M Renzetti, P M Paciorek, S A Tannu, N C Rinaldi, J E Tocker, M A Wasserman and P R Gater
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 847-853;

  9. Tawfik, S

    1. Mechanisms of nonlinear pharmacokinetics of mibefradil in chronically instrumented dogs.
      A Skerjanec, S Tawfik and Y K Tam
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 817-825;

  10. Terasaki, T

    1. Comparative distribution of quinolone antibiotics in cerebrospinal fluid and brain in rats and dogs.
      T Ooie, H Suzuki, T Terasaki and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 590-596;

  11. Thompson, A C

    1. Role of extracellular dopamine in the initiation and long-term expression of behavioral sensitization to cocaine.
      C A Heidbreder, A C Thompson and T S Shippenberg
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 490-502;

  12. Tocker, J E

    1. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways.
      L M Renzetti, P M Paciorek, S A Tannu, N C Rinaldi, J E Tocker, M A Wasserman and P R Gater
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 847-853;

  13. Tokuno, T

    1. Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle.
      K Muraki, H Nakagawa, N Nagano, S Henmi, H Kawasumi, T Nakanishi, K Imaizumi, T Tokuno, K Atsuki, Y Imaizumi and M Watanabe
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 555-563;

  14. Trendelenburg, A U

    1. The presynaptic alpha-2 autoreceptors in pig brain cortex are alpha-2A.
      A U Trendelenburg, N Limberger and K Starke
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 462-467;

  15. Trok, K

    1. A comparison of the effects of glial cell line-derived neurotrophic factor on spinal cord and cortex cerebri grafts.
      K Trok, S Almström and L Olson
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 941-949;

  16. Tuck, M L

    1. Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation.
      M D Nyby, M Sasaki, Y Ideguchi, H E Wynne, M T Hori, M E Berger, M S Golub, A S Brickman and M L Tuck
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 503-509;

U

  1. Undem, B J

    1. Inhibition by zinc protoporphyrin-IX of vasoactive intestinal peptide-induced relaxations of guinea pig isolated trachea.
      B J Undem, J L Ellis, S Meeker, A Fischer and B J Canning
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 964-970;

  2. Urrutia, A

    1. Cloning and functional characterization of human heteromeric N-methyl-D-aspartate receptors.
      S D Hess, L P Daggett, J Crona, C Deal, C C Lu, A Urrutia, L Chavez-Noriega, S B Ellis, E C Johnson and G Veliçelebi
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 808-816;

V

  1. Valentine, J L

    1. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats.
      J L Valentine, M Mayersohn, W D Wessinger, L W Arnold and S M Owens
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 709-716;
    2. Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats.
      J L Valentine and S M Owens
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 717-724;

  2. van der Staay, F J

    1. Effects of metrifonate, its transformation product dichlorvos, and other organophosphorus and reference cholinesterase inhibitors on Morris water escape behavior in young-adult rats.
      F J van der Staay, V C Hinz and B H Schmidt
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 697-708;

  3. Vassalle, M

    1. Ca(++)-dependence of caffeine modulation of the rate-force relation in canine cardiac Purkinje fibers.
      H Satoh and M Vassalle
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 826-835;

  4. Veasey, S C

    1. WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135.
      C A Fornal, C W Metzler, R A Gallegos, S C Veasey, A C McCreary and B L Jacobs
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 752-762;

  5. Veliçelebi, G

    1. Cloning and functional characterization of human heteromeric N-methyl-D-aspartate receptors.
      S D Hess, L P Daggett, J Crona, C Deal, C C Lu, A Urrutia, L Chavez-Noriega, S B Ellis, E C Johnson and G Veliçelebi
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 808-816;

  6. Villalobos, A R

    1. Mechanism mediating basolateral transport of 2,4-dichlorophenoxyacetic acid in rat kidney.
      A R Villalobos, C A Dunnick and J B Pritchard
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 582-589;

W

  1. Wagstaff, J D

    1. Microdialysis assessment of methamphetamine-induced changes in extracellular neurotensin in the striatum and nucleus accumbens.
      J D Wagstaff, J W Gibb and G R Hanson
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 547-554;

  2. Walsh, S L

    1. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans.
      K J Schuh, S L Walsh, G E Bigelow, K L Preston and M L Stitzer
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 836-846;

  3. Wang, G F

    1. Vascular hyporesponsiveness in aorta from portal hypertensive rats: possible sites of involvement.
      Y T Huang, G F Wang, M C Yang, S P Chang, H C Lin and C Y Hong
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 535-541;

  4. Wang, H

    1. Chloramphenicol and the inflammatory response in the rat. Upregulation of the gene for T2-kininogen in liver.
      P Raymond, H Wang, C Blais, A Décarie, A Adam and R Morais
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 934-940;

  5. Washburn, M S

    1. Block of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors by polyamines and polyamine toxins.
      M S Washburn and R Dingledine
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 669-678;

  6. Wasserman, M A

    1. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways.
      L M Renzetti, P M Paciorek, S A Tannu, N C Rinaldi, J E Tocker, M A Wasserman and P R Gater
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 847-853;

  7. Watanabe, M

    1. Effects of ONO-1101, a novel beta-antagonist, on action potential and membrane currents in cardiac muscle.
      K Muraki, H Nakagawa, N Nagano, S Henmi, H Kawasumi, T Nakanishi, K Imaizumi, T Tokuno, K Atsuki, Y Imaizumi and M Watanabe
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 555-563;

  8. Watkins, L R

    1. Morphine-induced alterations in antibody levels: receptor and immune mechanisms.
      L L Lockwood, L H Silbert, M R Fleshner, C McNeal, L R Watkins, M L Laudenslager, K C Rice, R J Weber and S F Maier
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 689-696;

  9. Weber, R J

    1. Morphine-induced alterations in antibody levels: receptor and immune mechanisms.
      L L Lockwood, L H Silbert, M R Fleshner, C McNeal, L R Watkins, M L Laudenslager, K C Rice, R J Weber and S F Maier
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 689-696;

  10. Wessinger, W D

    1. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats.
      J L Valentine, M Mayersohn, W D Wessinger, L W Arnold and S M Owens
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 709-716;

  11. Wilmot, C A

    1. Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity.
      A M Szczepanik, L R Brougham, J E Roehr, P G Conway, D B Ellis and C A Wilmot
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 913-920;

  12. Wong, P Y

    1. Leukotriene B4 modulates in vivo expression of delayed-type hypersensitivity by a receptor-mediated mechanism: regulation by lipoxin A4.
      Z Feng, H P Godfrey, S Mandy, S Strudwick, K T Lin, E Heilman and P Y Wong
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 950-956;

  13. Wynne, H E

    1. Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation.
      M D Nyby, M Sasaki, Y Ideguchi, H E Wynne, M T Hori, M E Berger, M S Golub, A S Brickman and M L Tuck
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 503-509;

Y

  1. Yamada, T

    1. The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123.
      H C Shin, Y Kato, Y Shitara, T Yamada, T Nakamura, A Hisaka and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 607-613;

  2. Yamashita, N

    1. A nitric oxide donor reverses myocardial injury in rabbits with acute hypercholesterolemia.
      S Hoshida, N Yamashita, J Igarashi, M Nishida, M Hori, T Kuzuya and M Tada
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 741-746;

  3. Yang, M C

    1. Vascular hyporesponsiveness in aorta from portal hypertensive rats: possible sites of involvement.
      Y T Huang, G F Wang, M C Yang, S P Chang, H C Lin and C Y Hong
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 535-541;

  4. Yano, M

    1. Carrier-mediated active transport of BQ-123, a peptidic endothelin antagonist, into rat hepatocytes.
      T Nakamura, A Hisaka, Y Sawasaki, Y Suzuki, T Fukami, K Ishikawa, M Yano and Y Sugiyama
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 564-572;

  5. Yu, D

    1. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration.
      R Zhang, R P Iyer, D Yu, W Tan, X Zhang, Z Lu, H Zhao and S Agrawal
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 971-979;

  6. Yuki, S

    1. Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model.
      H Kawai, S Yuki, J Sugimoto and Y Tamao
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 780-785;

Z

  1. Zamir, N

    1. Thrombin stimulates atrial natriuretic peptide secretion from rat cardiac atrium.
      L Klapper, S Nachshon, O Zamir and N Zamir
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 476-481;

  2. Zamir, O

    1. Thrombin stimulates atrial natriuretic peptide secretion from rat cardiac atrium.
      L Klapper, S Nachshon, O Zamir and N Zamir
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 476-481;

  3. Zarzuelo, A

    1. Effect of quercitrin on acute and chronic experimental colitis in the rat.
      F Sánchez de Medina, J Gálvez, J A Romero and A Zarzuelo
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 771-779;

  4. Zhang, R

    1. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration.
      R Zhang, R P Iyer, D Yu, W Tan, X Zhang, Z Lu, H Zhao and S Agrawal
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 971-979;

  5. Zhang, X

    1. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration.
      R Zhang, R P Iyer, D Yu, W Tan, X Zhang, Z Lu, H Zhao and S Agrawal
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 971-979;

  6. Zhao, H

    1. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration.
      R Zhang, R P Iyer, D Yu, W Tan, X Zhang, Z Lu, H Zhao and S Agrawal
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 971-979;

  7. Zhou, Q

    1. Pharmacologic characteristics of potentiation of 5-HT3 receptors by alcohols and diethyl ether in NCB-20 neuroblastoma cells.
      Q Zhou and D M Lovinger
      Journal of Pharmacology and Experimental Therapeutics August 1996, 278 (2) 732-740;
Back to top

In this issue